However, a recent meta-analysis highlighted that the use of GLP-1 receptor agonists does not modify the risk of bone fracture in patients with type 2 diabetes compared with the use of other antidiabetic medications29. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.